医学
四分位间距
糖尿病
血糖性
胰岛素
2型糖尿病
糖尿病管理
随机对照试验
1型糖尿病
血糖自我监测
内科学
临床终点
外科
连续血糖监测
内分泌学
作者
Mikkel Thor Olsen,Carina Kirstine Klarskov,Simon Storgård Jensen,Louise M. Rasmussen,Birgitte Lindegaard,Jonas Askø Andersen,Hans Gottlieb,Suzanne Lunding,Ulrik Pedersen‐Bjergaard,Katrine Bagge Hansen,Peter Lommer Kristensen
出处
期刊:Diabetes Care
[American Diabetes Association]
日期:2025-01-31
摘要
OBJECTIVE The DIATEC trial investigates the glycemic and clinical effects of inpatient continuous glucose monitoring (CGM)–guided insulin titration by diabetes teams. RESEARCH DESIGN AND METHODS This two-center trial randomized 166 non–intensive care unit patients with type 2 diabetes. Diabetes management was performed by regular staff, guided by diabetes teams using insulin titration algorithms based on either point-of-care glucose testing or CGM. The primary outcome was the difference in time in range (TIR) (3.9–10.0 mmol/L) between the two arms. Outcomes were assessed during hospitalization. RESULTS The CGM arm achieved a higher median (interquartile range [IQR]) TIR of 77.6% (24.4%) vs. 62.7% (31.5%) in the POC arm (P < 0.001). Median (IQR) time above range (TAR) >10.0 mmol/L was lower in the CGM arm at 21.1% (24.8%) vs. 36.5% (30.3%) in the POC arm (P = 0.001), and time below range (TBR) <3.9 mmol/L was reduced by CGM, with a relative difference to POC of 0.57 (95% CI 0.34–0.97; P = 0.042). Prolonged hypoglycemic events decreased (incidence rate ratio [IRR] 0.13; 95% CI 0.04–0.46; P = 0.001), and the mean (SD) coefficient of variation was lower in the CGM arm at 25.4% (6.3%) vs. 28.0% (8.2%) in the POC arm (P = 0.024). Mean (SD) total insulin doses were reduced in the CGM arm at 24.1 (13.9) vs. 29.3 (13.9) IU/day in the POC arm (P = 0.049). A composite of complications was lower in the CGM arm (IRR 0.76; 95% CI 0.59–0.98; P = 0.032). CONCLUSIONS In-hospital CGM increased TIR by 15 percentage points, mainly by reducing TAR. CGM also lowered TBR, glycemic variability, prolonged hypoglycemic events, insulin usage, and in-hospital complications.
科研通智能强力驱动
Strongly Powered by AbleSci AI